Pages that link to "Q58814289"
Jump to navigation
Jump to search
The following pages link to Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) (Q58814289):
Displaying 41 items.
- Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies (Q33399543) (← links)
- Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. (Q33952823) (← links)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr (Q34044024) (← links)
- Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies (Q34568898) (← links)
- Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response (Q35043077) (← links)
- Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes (Q35061893) (← links)
- Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine–melphalan conditioning for treatment of mature T-cell lymphomas (Q35087581) (← links)
- Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901 (Q35100217) (← links)
- A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients (Q35218515) (← links)
- Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation (Q36092021) (← links)
- Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab (Q36219690) (← links)
- Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience. (Q36612548) (← links)
- Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (Q36711793) (← links)
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse (Q36741749) (← links)
- Management of indolent lymphoma: where are we now and where are we going (Q36784860) (← links)
- Non-Hodgkin's lymphomas, version 4.2014. (Q36820885) (← links)
- Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma (Q36834194) (← links)
- Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (Q36964464) (← links)
- Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party (Q36967098) (← links)
- Role of hematopoietic stem cell transplant in the management of follicular lymphoma (Q37533977) (← links)
- Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. (Q37552077) (← links)
- Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma (Q37738497) (← links)
- Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients (Q37741004) (← links)
- Non-myeloablative umbilical cord blood transplantation (Q37788412) (← links)
- Transplantation for non-Hodgkin lymphoma (Q37810079) (← links)
- Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia (Q37824996) (← links)
- Stem cell transplantation for indolent lymphoma: a reappraisal (Q37884884) (← links)
- Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status (Q38108320) (← links)
- Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation (Q38488058) (← links)
- Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. (Q39933774) (← links)
- Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas (Q40015002) (← links)
- Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia (Q40817438) (← links)
- Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma (Q43205090) (← links)
- Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. (Q44065098) (← links)
- Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. (Q46719541) (← links)
- Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation (Q47142550) (← links)
- Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (Q47588374) (← links)
- Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. (Q50051516) (← links)
- The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. (Q51804258) (← links)
- Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation (Q83951403) (← links)
- Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT (Q85637066) (← links)